13F Insight
DOSSIER · 13F-HR · Q2 2026

PFM Health Sciences, LP

$1.2B in tracked AUM across 98 positions as of Q2 2026.

PH
CIK 0001442756 · last filed Jun 30, 2026
Total AUM
$1.2B
as of Q2 2026
Holdings
98
—
positions
Whale Score
60
60
tracked
Activity
—
no data
changes this Q
AI Analysis · Q2 2026
Comprehensive Analysis of PFM Health Sciences, LP SEC 13F Filing
Portfolio Overview

As of the report date September 30, 2025, PFM Health Sciences, LP manages a portfolio valued at approximately $716.87 million across 38 holdings. This represents a significant contraction in assets under management (AUM), with the portfolio value decreasing by 39.0% from the previous quarter's $1.17 billion. This reduction is driven by a combination of market performance and substantial capital reallocatio...

The portfolio is highly concentrated, reflecting a high-conviction investment strategy. The top ten holdings account for roughly 68% of the total portfolio value, with the largest position, Tenet Healthcare (THC), constituting 13.08% alone. The fund maintains a clear focus on the healthcare sector, utilizing both specific stock picks and ETFs to execute its strategy.

Key Holdings
Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
K08588103
ASCENDIS PHARMA A/S
$62M233K5.3%02
AXSM
AXSOME THERAPEUTICS INC.
$54M220K4.6%03
LLY
ELI LILLY & CO
$47M39K4.0%04
G50871105
JAZZ PHARMACEUTICALS PLC
$39M161K3.3%05
HUM
HUMANA INC
$37M94K3.2%06
UNH
UNITEDHEALTH GROUP INC
$37M88K3.1%07
NBIX
NEUROCRINE BIOSCIENCES INC
$36M213K3.1%08
INBX
INHIBRX BIOSCIENCES INC
$29M308K2.5%09
UTHR
UNITED THERAPEUTICS CORP DEL
$27M50K2.3%10
RVMD
REVOLUTION MEDICINES INC
$27M143K2.3%

Filing history

2026Q2Jun 30
$1.2B▲ 6.3%
98 positionsView →2026Q1Mar 31
$1.1B▲ 9.3%
83 positionsView →2025Q4Dec 31
$1.0B▲ 39.9%
78 positionsView →2025Q3Sep 30
$717M▼ 39.0%
38 positionsView →2025Q2Jun 30
$1.2B▲ 48.0%
57 positionsLocked2025Q1Mar 31
$794M▼ 50.8%
43 positionsLocked2024Q4Dec 31
$1.6B▼ 8.6%
83 positionsLocked2024Q3Sep 30
$1.8B▼ 12.7%
75 positionsLocked2024Q2Jun 30
$2.0B▼ 5.0%
78 positionsLocked2024Q1Mar 31
$2.1B▲ 27.6%
87 positionsLocked2023Q4Dec 31
$1.7B▼ 21.5%
65 positionsLocked2023Q3Sep 30
$2.1B▼ 17.6%
73 positionsLocked
Showing 12 of 65